Back to Awarded Treatment Trials
Awarded Trial: 01T-411
Grant ID
01T-411
Illness
Schizophrenia
Primary Drug/Intervention
Galantamine
Primary Dosage
24 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Buchanan
Sample Size
80
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
Cognitive battery
Results
Eighty-six patients were enrolled and 73 completed the trial. Galantamine treatment did not differ from placebo on a composite score of cognitive measures but did show a benefit on verbal memory and the digit-symbol subtest.
Publication
Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008;165:82-89.
Link
http://www.ncbi.nlm.nih.gov/pubmed/17986678
PI Name
Robert Buchanan
Degree
MD
Center
Maryland Psychiatric Research Center
Institution
University of Maryland
Address
P.O. Box 21247
City or Town
Baltimore
State or Province
MD
Zip or Postal Code
21228
Country
USA
Email Address
rwbuchanan@mprc.umaryland.edu